Discordant effects of interleukin-2 on viral and immune parameters in human immunodeficiency virus-1-infected monocyte-derived mature dendritic cells

Clinical and Experimental Immunology

Volumn 132, Issue 2, 2003, Pages 289-296

  Bahr, George M ^a   Darcissac, E C A ^a   Mouton, Y ^a,b  

^a INSTITUT PASTEUR DE LILLE   (France)

^b Dron Hospital   (France)

Author keywords

Antigen presenting cells; Chemokines; HIV 1; IL 2; Virus receptors

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL DIFFERENTIATION; CELL STIMULATION; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IN VITRO STUDY; MACROPHAGE; MONOCYTE; NONHUMAN; PARAMETER; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIGENS, CD4; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; GENE EXPRESSION; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2; MACROPHAGES; RECEPTORS, CCR5; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

EID: 0037541413     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02143.x     Document Type: Article

References (43)

1. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci USA 1999; 96:10958-61.
2. Rinaldo CR Jr, Liebmann JM, Huang XL et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999; 179:329-36.
3. Connick E, Lederman MM, Kotzin BL et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000; 181:358-63.
4. Mitsuyasu R. Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients. J Infect Dis 2002; 185 (Suppl. 2):S115-22.
5. Imami N, Gotch F. Prospects for immune reconstitution in HIV-1 infection. Clin Exp Immunol 2002; 127:402-11.
6. Kelleher AD, Roggensack M, Emery S et al. Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. Clin Exp Immunol 1998; 113:85-91.
7. Dybul M, Hidalgo B, Chun TW et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 2002; 185:61-8.
8. Hodge S, Hodge G, Flower R et al. Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood. Scand J Immunol 2000; 51:67-72.
9. Bosco MC, Pulkki K, Rowe TK et al. IL-4 inhibits IL-2-induced tumoricidal activity and secretory functions of human monocytes. Modulation of IL-2 binding and IL-2 receptor beta gamma chain expression. J Immunol 1995; 155:1411-9.
10. David D, Bani L, Moreau JL et al. Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets. Blood 1998; 91:165-72.
11. Fukao T, Koyasu S. Expression of functional IL-2 receptors on mature splenic dendritic cells. Eur J Immunol 2000; 30:1453-7.
12. Kradin RL, Xia W, Pike M et al. Interleukin-2 promotes the motility of dendritic cells and their accumulation in lung and skin. Pathobiology 1996; 64:180-6.
13. Cluítmans FH, Esendam BH, Landegent JE et al. IL-4 down-regulates IL-2-, IL-3-, and GM-CSF-induced cytokine gene expression in peripheral blood monocytes. Ann Hematol 1994; 68:293-8.
14. Musso T, Johnston JA, Linnekin D et al. Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7. J Exp Med 1995; 181:1425-31.
15. Bosco MC, Curiel RE, Zea AH et al. IL-2 signaling in human monocytes involves the phosphorylation and activation of p59hck. J Immunol 2000; 164:4575-85.
16. McBride WH, Economou JS, Nayersina R et al. Influences of interleukins 2 and 4 on tumor necrosis factor production by murine mononuclear phagocytes. Cancer Res 1990; 50:2949-52.
17. Faulkner L, Buchan G, Lockhart E et al. IL-2 linked to a peptide from influenza hemagglutinin enhances T cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells. Int Immunol 2001; 13:713-21.
18. Kronin V, Vremec D, Shortman K. Does the IL-2 receptor alpha chain induced on dendritic cells have a biological function? Int Immunol 1998; 10:237-40.
19. Granucci F, Vizzardelli C, Pavelka N et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol 2001; 2:882-8.
20. Kinter AL, Poli G, Fox L et al. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995; 154:2448-59.
21. Unutmaz D, Kewa I, Ramani VN et al. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med 1999; 189:1735-46.
22. Blanco J, Cabrera C, Jou A et al. Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. AIDS 1999; 13:547-55.
23. Bovolenta C, Camorali L, Lorini AL et al. In vivo administration of recombinant IL-2 to individuals infected by HIV down-modulates the binding and expression of the transcription factors ying-yang-1 and leader binding protein-1/late simian virus 40 factor. J Immunol 1999; 163:6892-7.
24. Truong MJ, Darcissac EC, Hermann E et al. Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic cells. J Virol 1999; 73:7008-13.
25. + lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice. J Virol 2001; 75:6941-52.
26. Cecilia D, Kewa I, Ramani VN et al. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 1998; 72:6988-96.
27. Hermann E, Darcissac E, Idziorek T et al. Recombinant interleukin-16 selectively modulates surface receptor expression and cytokine release in macrophages and dendritic cells. Immunology 1999; 97:241-8.
28. Darcissac EC, Truong MJ, Dewulf J et al. The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells. J Virol 2000; 74:7794-802.
29. Yi Y, Rana S, Turner JD et al. CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:772-7.
30. Waldmann TA. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993; 14:264-70.
31. Shearer GM. HIV-induced immunopathogenesis. Immunity 1998; 9:587-93.
32. Bahr GM. Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunomodulator murabutide. J Antimicrob Chemother 2003; 51:5-8.
33. Schmidtmayerova H, Alfano M, Nuovo G et al. Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J Virol 1998; 72:4633-42.
34. Collman RG, Yi Y. Cofactors for human immunodeficiency virus entry into primary macrophages. J Infect Dis 1999; 179 (Suppl. 3):S422-6.
35. Kutza J, Hayes MP, Clouse KA. Interleukin-2 inhibits HIV-1 replication in human macrophages by modulating expression of CD4 and CC-chemokine receptor-5. AIDS 1998; 12:F59-64.
36. - T cells using a combination of cytokines. J Exp Med 1998; 188:83-91.
37. Poli G, Bressler P, Kinter A et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and posttranscriptional mechanisms. J Exp Med 1990; 172:151-8.
38. + T cells after bacterial stimulation. J Infect Dis 2000; 181:2041-4.
39. Theze J, Alzari PM, Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol Today 1996; 17:481-6.
40. Miyazaki T, Liu ZJ, Kawahara A et al. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 1995; 81:223-31.
41. Emilie D, Galanaud P. Cytokines and chemokines in HIV infection: implications for therapy. Int Rev Immunol 1998; 16:705-26.
42. Bonder CS, Dickensheets HL, Finlay-Jones JJ et al. Involvement of the IL-2 receptor gamma-chain (gammac) in the control by IL-4 of human monocyte and macrophage proinflammatory mediator production. J Immunol 1998; 160:4048-56.
43. Weiden M, Tanaka N, Qiao Y et al. Differentiation of monocytes to macrophages switches the Mycobacterium tuberculosis effect on HIV-1 replication from stimulation to inhibition: modulation of interferon response and CCAAT/enhancer binding protein beta expression. J Immunol 2000; 165:2028-39.